血液透析中心静脉导管的临床与监管考量
本文讨论了维持性血液透析患者中心静脉导管在临床与监管方面的重要考量。一个由学术界、产业界和美国食品药品监督管理局代表组成的工作组识别了导管的主要设计考量及临床与监管挑战,旨在促进对这类器械的理解并为推动创新奠定基础。
要点
- 中心静脉导管仍是维持性血液透析患者的重要血管通路选择。
- 需对导管进行透明、全面的监管审查以激励创新并改善患者结局。
- 多利益相关方合作有助于明确导管设计考量与临床监管挑战。
核心结论
- 中心静脉导管对维持性血液透析患者至关重要,其创新和透明的监管审查对改善患者结局必不可少。
研究设计与样本
- convened a workgroup including representatives from academia, industry, and the US Food and Drug Administration to identify major design considerations and clinical and regulatory challenges of central venous catheters for hemodialysis.
主要发现
- 工作组识别了血液透析中心静脉导管的主要设计考量及临床与监管挑战。
临床怎么用
- 临床应重视中心静脉导管作为维持性血液透析血管通路的重要选择,并关注其设计创新与监管审查进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central venous catheters remain a vital option for access for patients receiving maintenance hemodialysis. There are many important and evolving clinical and regulatory considerations for all stakeholders for these devices. Innovation and transparent and comprehensive regulatory review of these devices is essential to stimulate innovation to help promote better outcomes for patients receiving maintenance hemodialysis. A workgroup that included representatives from academia, industry, and the US Food and Drug Administration was convened to identify the major design considerations and clinical and regulatory challenges of central venous catheters for hemodialysis. Our intent is to foster improved understanding of these devices and provide the foundation for strategies to foster innovation of these devices.
引用
- Silverstein DM, Trerotola SO, Clark T, et al. Clinical and Regulatory Considerations for Central Venous Catheters for Hemodialysis. Clin J Am Soc Nephrol. 2018. PMID: 30309840. doi:10.2215/CJN.14251217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。